We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Pramlintide (amylin analog)
An FDA-approved synthetic analog of the beta-cell hormone amylin (brand Symlin), injected before meals as an adjunct to mealtime insulin in type 1 and type 2 diabetes. Honest appraisal: this is a real prescription drug, not a supplement, with genuine but modest efficacy. It carries a US FDA BOXED WARNING for severe insulin-induced hypoglycemia (especially in type 1 diabetes), commonly causes nausea, and requires reducing mealtime insulin when starting. It is not a supplement and is not auto-recommended.
Prescription medication — not a dietary supplement
Pramlintide is a prescription (or investigational) drug, not a supplement. It is included here for reference because people research and discuss it (often used off-label) — not as a recommendation. Take it only under a qualified clinician's supervision and only as prescribed; do not source it from grey-market vendors, where identity, purity, and dosing are unverified. The evidence below reflects its clinical trials.
What the evidence says
Pramlintide doesn't have enough studies with structured effect-size data yet to pool a verdict. Browse the studies below for individual findings.
Most evidence is from high-quality meta-analyses and randomised trials published 1997–2026 with a typical study size of 3,297 participants.
Based on 87 studies · 5 meta-analyses · 65 RCTs · 3,297 total participants
Confidence
High confidenceBy outcome
Scores Moderate (5) as an FDA-approved drug with multiple 52-week phase-3 RCTs and meta-analyses confirming real but modest benefits, offset by a boxed hypoglycemia warning.
64 randomised trials
92% were about Pramlintide in an audit of 50 of them
Every randomised or controlled trial of Pramlintide indexed in PubMed, not a hand-picked subset. Meta-analyses and systematic reviews are deliberately excluded from this count: most of them cover many compounds at once, so counting them would inflate it.
PubMed · as of Sep 2026
5 trials ongoing or recruiting · 44 completed on ClinicalTrials.gov
13 of the completed trials have posted results
Registered trials show research momentum for Pramlintide, not proof of effect — a registration is a plan, and posted results are sponsor-reported, not peer-reviewed. They are never counted toward the evidence rating above.
Browse these trials on ClinicalTrials.govClinicalTrials.gov · as of Nov 2026
Pramlintide is a soluble, non-aggregating synthetic analog of amylin — the 37-amino-acid beta-cell hormone that is co-secreted with insulin in response to meals.
It is a PRESCRIPTION DRUG, not a dietary supplement: branded as Symlin, it was approved by the US FDA in March 2005 as a subcutaneous, pre-meal injection used as an adjunct to mealtime insulin in patients with type 1 diabetes, and in patients with type 2 diabetes using mealtime insulin (with or without metformin and/or a sulfonylurea).
Mechanistically, amylin complements insulin in postprandial glucose regulation: it suppresses post-meal glucagon secretion, slows gastric emptying, and promotes satiety/reduces food intake. Pramlintide reproduces these effects in humans.
The evidence base is real and consists of multiple double-blind, placebo-controlled phase-3 RCTs plus meta-analyses, but the magnitude of benefit is modest. In trials, adding pramlintide to insulin produced modest improvements in HbA1c and weight, with nausea and hypoglycaemia risks.
Absolute HbA1c changes must be reported in percentage points, with the study, time point and comparator stated. Pramlintide carries a US FDA boxed warning for severe hypoglycaemia when used with insulin.
Starting it requires a prescriber-managed insulin plan and frequent glucose monitoring; do not adjust insulin yourself. The honest counterweight: pramlintide carries a US FDA BOXED WARNING for severe insulin-induced hypoglycemia.
The US Symlin label warns of severe hypoglycaemia when used with insulin, especially in type 1 diabetes. When it occurs, the label describes it within three hours after injection.
Starting Symlin requires a clinician-managed 50% reduction in mealtime insulin, including premixed insulin, with frequent glucose monitoring and subsequent individual adjustment. Do not change insulin doses on your own. Nausea is the most common side effect, usually mild-to-moderate and concentrated in the first weeks.
It must be injected separately from insulin (they cannot be mixed in one syringe). It should be used only under a clinician's care, for a genuine medical indication.
A synthetic analog of the beta-cell hormone amylin that activates the amylin receptor (the calcitonin receptor complexed with a receptor-activity-modifying protein, RAMP), largely via centrally-mediated effects — the upstream target driving its actions on glucagon, gastric emptying and satiety.
Suppresses the inappropriate post-meal rise in glucagon, reducing hepatic glucose output and blunting post-meal glucose excursions — complementing the action of mealtime insulin.
Delays gastric emptying so that nutrient (glucose) entry into the circulation is slowed, smoothing postprandial glucose spikes — and the mechanism behind much of the early nausea.
Acts on central appetite circuits to increase satiety and reduce energy intake, the driver of the modest weight loss seen in long-term trials (demonstrated directly in human meal-test studies).
How Pramlintide works — from molecular targets to health outcomes. Click an edge to see supporting research.This visualization is in beta — pathways are being refined and expanded.
Highest hypoglycemia risk; mealtime insulin must be reduced when starting and glucose closely monitored. US FDA boxed-warning population.
Generally avoid — the hypoglycemia risk in the US FDA boxed warning is unacceptable in those who cannot detect or reliably treat low glucose.
Contraindicated/avoid — pramlintide further slows gastric emptying.
Not established as safe; use only if clearly needed and under specialist supervision. Glycemic management in pregnancy is individualized by a clinician.
Not appropriate — this is a prescription drug indicated as an insulin adjunct, with a US FDA boxed warning. Use only for a clinician-confirmed indication.
The US Symlin label warns of severe hypoglycaemia when used with insulin, especially in type 1 diabetes. When it occurs, the label describes it within three hours after injection. Starting Symlin requires a clinician-managed 50% reduction in mealtime insulin, including premixed insulin, with frequent glucose monitoring and subsequent individual adjustment. Do not change insulin doses on your own.
Combining with other agents that lower glucose can additively increase hypoglycemia risk; clinician dose adjustment and monitoring are required.
By slowing gastric emptying, pramlintide can delay the absorption of co-administered oral drugs. Where a rapid onset is needed (e.g. analgesics, oral contraceptives, some antibiotics), take them at least 1 hour before or 2 hours after the pramlintide injection.
Agents that further slow GI motility (e.g. anticholinergics) or other drugs affecting gastric emptying may compound pramlintide's GI effects — clinician review advised.
Tip: Contact your treating team about the symptom and follow the product-specific instructions. Do not reduce, split, stop or restart prescribed treatment solely to continue this experiment. Monitor blood glucose frequently. Ensure the patient and family recognize and can treat hypoglycemia.
Tip: Contact your treating team about the symptom and follow the product-specific instructions. Do not reduce, split, stop or restart prescribed treatment solely to continue this experiment.
Tip: Contact your treating team about the symptom and follow the product-specific instructions. Do not reduce, split, stop or restart prescribed treatment solely to continue this experiment.
Tip: Often related to glycemic changes early in treatment; report persistent symptoms to a clinician
Tip: Rotate injection sites (abdomen/thigh)
Pramlintide has an evidence score of 5/10 — moderate evidence based on 87 indexed studies, including 2 meta-analyses. An FDA-approved synthetic analog of the beta-cell hormone amylin (brand Symlin), injected before meals as an adjunct to mealtime insulin in type 1 and type 2 diabetes. Honest appraisal: this is a real prescription drug, not a supplement, with genuine but modest efficacy. It carries a US FDA BOXED WARNING for severe insulin-induced hypoglycemia (especially in type 1 diabetes), commonly causes nausea, and requires reducing mealtime insulin when starting. It is not a supplement and is not auto-recommended. Representative study: PMID 29029531.
Dosing for Pramlintide: Prescription-only, clinician-titrated. Subcutaneous injection immediately before major meals. Type 1 diabetes: typically start 15 µg and titrate to 30-60 µg per meal. Type 2 diabetes (on mealtime insulin): typically start 60 µg and titrate to 120 µg per meal. Reduce mealtime insulin (often by ~50%) when starting. DO NOT self-dose. Individual needs vary, so check the right dose for you with a healthcare provider.
The best time to take Pramlintide is with meals. Take it with food. Injected subcutaneously immediately before each major meal (≥250 kcal or ≥30 g carbohydrate).
Pramlintide should be used with caution — talk to a healthcare provider before taking it. Reported side effects include severe insulin-induced hypoglycemia, nausea, vomiting / anorexia. How often they occur is not established for all of them. Use caution if any of these apply to you: Confirmed diagnosis of gastroparesis (slowed gastric emptying would be worsened); Hypoglycemia unawareness; Poor compliance with current insulin regimen or self-monitoring of blood glucose.
Semaglutide
Too few graded studiesAn FDA-approved GLP-1 receptor agonist (Ozempic/Rybelsus for type 2 diabetes, Wegovy for chronic weight management) with genuinely strong, large-RCT evidence for glycemic control and substantial weight loss, plus a cardiovascular-outcomes benefit. Honest appraisal: this is a real prescription medicine with real efficacy AND real risks — a US FDA boxed warning for thyroid C-cell tumors, pancreatitis and gallbladder risk, very common GI side effects, and growing concern about grey-market/compounded versions. It is a prescription drug, not a supplement, and is never auto-recommended.
Tirzepatide
Too few graded studiesAn FDA-approved prescription medication (Mounjaro for type 2 diabetes, Zepbound for obesity and obstructive sleep apnea), not a dietary supplement. Honest appraisal: in head-to-head phase-3 trials it is the most effective approved weight-loss drug to date — up to ~21% body-weight loss over 72 weeks and superior to semaglutide — but it is a real medicine with real risks: a US FDA boxed warning for thyroid C-cell tumors, common GI side effects, and pancreatitis/gallbladder signals. Do not source or use it outside a prescription.
Liraglutide
Too few graded studiesAn FDA-approved, once-daily GLP-1 receptor agonist (Victoza for type 2 diabetes, Saxenda for chronic weight management). Honest appraisal: a real prescription medicine with genuinely strong large-RCT evidence for glycemic control and moderate weight loss, plus a cardiovascular-outcomes benefit (LEADER). It also carries real risks — a US FDA boxed warning for thyroid C-cell tumors, pancreatitis and gallbladder risk, very common GI side effects, and lean-mass loss with weight loss. It is a prescription medicine, NOT a supplement, and is not auto-recommended.
Orforglipron
Too few graded studiesAn ORAL, non-peptide small-molecule GLP-1 receptor agonist for obesity, also studied in type 2 diabetes — the headline is the convenience of a once-daily pill (no injection, no cold chain, no food/water restrictions) delivering GLP-1-class glycemic and weight benefit. In the US, orforglipron is approved as Foundayo for long-term weight management in adults with obesity, or overweight with at least one weight-related condition, together with a reduced-calorie diet and increased physical activity. FDA approval was granted on 1 April 2026. An EMA list dated 5 October 2026 places orforglipron under evaluation. Honest appraisal: the phase-2 data are strong and the phase-3 read-outs (ATTAIN/ACHIEVE) are promising, but it has the full GLP-1-class side-effect burden (very common dose-dependent nausea/vomiting/diarrhea, higher discontinuation than injectables in some comparisons), the US label carries a boxed warning about thyroid C-cell tumours, and long-term outcomes are unsettled. It is NOT a dietary supplement.
Explore: Best supplements for Vitality & Longevity
Reviewed by Dr. Baher Al Hakim · Last reviewed June 2026 · evidence from 87 studies · how we score · editorial policy
This information is for educational purposes only. It is not a substitute for professional medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any supplement or medication.
Tap node to isolate • Pinch to zoom • Tap edge for research